Metastatic adult-type non-rhabdomyosarcoma soft tissue sarcomas in children and adolescents: A cohort study from the European paediatric Soft tissue sarcoma Study Group.
adolescents
children
metastases
non-rhabdomyosarcoma soft tissue sarcomas
outcome
prognostic factors
treatment
Journal
Cancer
ISSN: 1097-0142
Titre abrégé: Cancer
Pays: United States
ID NLM: 0374236
Informations de publication
Date de publication:
15 08 2023
15 08 2023
Historique:
revised:
01
03
2023
received:
16
01
2023
accepted:
22
03
2023
medline:
24
7
2023
pubmed:
21
4
2023
entrez:
21
04
2023
Statut:
ppublish
Résumé
Limited data exist on the clinical behavior of pediatric non-rhabdomyosarcoma soft tissue sarcomas (NRSTS) with distant metastases at onset, and a clear standard of care has not yet been defined. This cohort study reports on pediatric adult-type metastatic NRSTS enrolled in two concurrent prospective European studies, i.e., the randomized BERNIE study and the single-arm MTS 2008 study developed by the European paediatric Soft tissue sarcoma Study Group. Treatment programs were originally designed for patients with metastatic rhabdomyosarcoma, i.e., nine courses of multidrug chemotherapy (with or without bevacizumab in the BERNIE study), followed by 12 cycles of maintenance therapy, whereas radiotherapy and/or surgery (on primary tumor and/or metastases) were delayed until after seven courses of chemotherapy had been administered. The study included 61 patients <21 years old treated from July 2008 to December 2016. The lung was the site of metastases in 75% of the cases. All patients received multi-agent chemotherapy, 44% had local therapy to primary tumor, and 18% had treatment of metastases. Median time to progression/relapse was 6 months. A high rate of tumor progression was observed during the initial part of the chemotherapy program. With a median follow-up of 41.5 months (range, 2-111 months), 3-year event-free survival and overall survival were 15.4% (95% confidence interval [CI], 7.6-25.7) and 34.9% (95% CI, 22.7-47.5), respectively. There were no statistically significant differences in outcome depending on the type of treatment administered. The study confirmed the overall poor outcome for patients with metastatic NRSTS, whose treatment remains a challenge. Pediatric non-rhabdomyosarcoma soft tissue sarcomas form a heterogeneous group of rare tumors. Although recent international studies have defined the standard of care for patients with localized disease, limited data are available on the clinical behavior of patients with distant metastases. This study on 61 metastatic cases treated on two prospective European protocols confirms that the chances of survival of such patients are often dismal and a standard treatment is still lacking.
Sections du résumé
BACKGROUND
Limited data exist on the clinical behavior of pediatric non-rhabdomyosarcoma soft tissue sarcomas (NRSTS) with distant metastases at onset, and a clear standard of care has not yet been defined.
METHODS
This cohort study reports on pediatric adult-type metastatic NRSTS enrolled in two concurrent prospective European studies, i.e., the randomized BERNIE study and the single-arm MTS 2008 study developed by the European paediatric Soft tissue sarcoma Study Group. Treatment programs were originally designed for patients with metastatic rhabdomyosarcoma, i.e., nine courses of multidrug chemotherapy (with or without bevacizumab in the BERNIE study), followed by 12 cycles of maintenance therapy, whereas radiotherapy and/or surgery (on primary tumor and/or metastases) were delayed until after seven courses of chemotherapy had been administered.
RESULTS
The study included 61 patients <21 years old treated from July 2008 to December 2016. The lung was the site of metastases in 75% of the cases. All patients received multi-agent chemotherapy, 44% had local therapy to primary tumor, and 18% had treatment of metastases. Median time to progression/relapse was 6 months. A high rate of tumor progression was observed during the initial part of the chemotherapy program. With a median follow-up of 41.5 months (range, 2-111 months), 3-year event-free survival and overall survival were 15.4% (95% confidence interval [CI], 7.6-25.7) and 34.9% (95% CI, 22.7-47.5), respectively. There were no statistically significant differences in outcome depending on the type of treatment administered.
CONCLUSIONS
The study confirmed the overall poor outcome for patients with metastatic NRSTS, whose treatment remains a challenge.
PLAIN LANGUAGE SUMMARY
Pediatric non-rhabdomyosarcoma soft tissue sarcomas form a heterogeneous group of rare tumors. Although recent international studies have defined the standard of care for patients with localized disease, limited data are available on the clinical behavior of patients with distant metastases. This study on 61 metastatic cases treated on two prospective European protocols confirms that the chances of survival of such patients are often dismal and a standard treatment is still lacking.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2542-2552Subventions
Organisme : Department of Health
Pays : United Kingdom
Informations de copyright
© 2023 American Cancer Society.
Références
Ferrari A, Sultan I, Huang TT, et al. Soft tissue sarcoma across the age spectrum: a population-based study from the Surveillance Epidemiology and End Results database. Pediatr Blood Cancer. 2011;57(6):943-949. doi:10.1002/pbc.23252
WHO Classification of Tumours Editorial Board. Soft tissue and bone tumours. In: WHO classification of tumours series. Vol 3. 5th ed., International Agency for Research on Cancer; 2020. ISBN 978-92-832-4502-5 https://publications.iarc.fr/588
Pfister SM, Reyes-Múgica M, Chan JKC, et al. A summary of the inaugural WHO Classification of Pediatric Tumors: transitioning from the optical into the molecular era. Cancer Discov. 2022;12(2):331-355. doi:10.1158/2159-8290.CD-21-1094
Spunt SL, Million L, Chi Y-Y, et al. A risk-based treatment strategy for non-rhabdomyosarcoma soft-tissue sarcomas in patients younger than 30 years (ARST0332): a Children’s Oncology Group prospective study. Lancet Oncol. 2020;21(1):145-161, doi:10.1016/s1470-2045(19)30672-2
Ferrari A, van Noesel MM, Brennan B, et al. Pediatric non-rhabdomyosarcoma soft tissue sarcomas: the prospective NRSTS 2005 study by the European pediatric Soft tissue sarcoma Study Group (EpSSG). Lancet Child Adolesc Health. 2021;5(8):546-558, doi:10.1016/s2352-4642(21)00159-0
Ferrari A, Brennan B, Casanova M, et al. Pediatric non-rhabdomyosarcoma soft tissue sarcomas: standard of care and treatment recommendations from the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG). Cancer Manag Res. 2022;14:2885-2902, doi:10.2147/cmar.s368381
Spunt SL, Poquette CA, Hurt YS, et al. Prognostic factors for children and adolescents with surgically resected non-rhabdomyosarcoma soft tissue sarcoma: an analysis of 121 patients treated at St Jude Children’s Research Hospital. J Clin Oncol. 1999;17(12):3697-3705. doi:10.1200/jco.1999.17.12.3697
Spunt SL, Hill DA, Motosue AM, et al. Clinical features and outcome of initially unresected nonmetastatic pediatric non-rhabdomyosarcoma soft tissue sarcoma. J Clin Oncol. 2002;20(15):3225-3235. doi:10.1200/jco.2002.06.066
Ferrari A, Casanova M, Collini P, et al. Adult-type soft tissue sarcomas in pediatric-age patients: experience at the Istituto Nazionale Tumori in Milan. J Clin Oncol. 2005;23(18):4021-4030. doi:10.1200/jco.2005.02.053
Ferrari A, Miceli R, Casanova M, et al. Adult-type soft tissue sarcomas in pediatric age: a nomogram-based prognostic comparison with adult sarcomas. Eur J Cancer. 2007;43:2691-2697.
Ferrari A, Orbach D, Sparber-Sauer M, et al. The treatment approach to pediatric non-rhabdomyosarcoma soft tissue sarcomas: a critical review from the INternational Soft Tissue SaRcoma ConsorTium. Eur J Cancer. 2022;169:10-19, doi:10.1016/j.ejca.2022.03.028
Weiss AR, Chen YL, Scharschmidt TJ, et al. Pathological response in children and adults with large unresected intermediate-grade or high-grade soft tissue sarcoma receiving preoperative chemoradiotherapy with or without pazopanib (ARST1321): a multicentre, randomised, open-label, phase 2 trial. Lancet Oncol. 2020;21(8):1110-1122, doi:10.1016/s1470-2045(20)30325-9
Pratt CB, Maurer HM, Gieser P, et al. Treatment of unresectable or metastatic pediatric soft tissue sarcomas with surgery, irradiation, and chemotherapy: a Pediatric Oncology Group study. Med Pediatr Oncol. 1998;30(4):201-209. doi:10.1002/(sici)1096-911x(199804)30:4<201::aid-mpo1>3.0.co;2-k
Pappo AS, Rao BN, Jenkins JJ, et al. Metastatic non-rhabdomyosarcomatous soft-tissue sarcomas in children and adolescents: the St. Jude Children's Research Hospital experience. Med Pediatr Oncol. 1999;33(2):76-82. doi:10.1002/(sici)1096-911x(199908)33:2<76::aid-mpo3>3.0.co;2-b
Chisholm JC, Merks JHM, Casanova M, et al. Open-label, multicentre, randomised, phase II study of the EpSSG and the ITCC evaluating the addition of bevacizumab to chemotherapy in childhood and adolescent patients with metastatic soft tissue sarcoma (the BERNIE study). Eur J Cancer 2017;83:177-184, doi:10.1016/j.ejca.2017.06.015
Ferrari A, Merks JHM, Chisholm JC, et al. Outcomes of metastatic non-rhabdomyosarcoma soft tissue sarcomas (NRSTS) treated within the BERNIE study: a randomised, phase II study evaluating the addition of bevacizumab to chemotherapy. Eur J Cancer. 2020;130:72-80. doi:10.1016/j.ejca.2020.01.029
Schoot RA, Chisholm JC, Casanova M, et al. Metastatic rhabdomyosarcoma: results of the European Paediatric Soft Tissue Sarcoma Study Group MTS 2008 study and pooled analysis with the concurrent BERNIE study. J Clin Oncol. 2022;40(32):3730-3740. doi:10.1200/jco.21.02981
Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92(3):205-216.
van Houwelingen HC. Dynamic prediction by landmarking in event history analysis. Scand J Stat. 2007;34(1):70-85. doi:10.1111/j.1467-9469.2006.00529.x
Antman K, Crowley J, Balcerzak SP, et al. An intergroup Phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol. 1993;11(7):1276-1285. doi:10.1200/jco.1993.11.7.1276
Judson I, Verweij J, Gelderblom H, et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled Phase 3 trial. Lancet Oncol. 2014;15(4):415-423. doi:10.1016/s1470-2045(14)70063-4
Gronchi A, Miah AB, Dei Tos AP, et al. Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32(11):1348-1365, doi:10.1016/j.annonc.2021.07.006
Bisogno G, De Salvo GL, Bergeron C, et al. Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomized, phase 3 trial. Lancet Oncol. 2019;20(11):1566-1575. doi:10.1016/s1470-2045(19)30617-5
Shah NK, Yegya-Raman N, Jones JA, Shabason JE. Radiation therapy in metastatic soft tissue sarcoma: from palliation to ablation. Cancers (Basel). 2021;13(19):4775. doi:10.3390/cancers13194775
Reddy VK, Jain V, Venigalla S, et al. Definitive local therapy is associated with improved survival in metastatic soft tissue sarcomas. Cancers (Basel). 2021;13(5):93. doi:10.3390/cancers13050932
Navarria P, Baldaccini D, Clerici E, et al. Stereotactic body radiation therapy for lung metastases from sarcoma in oligometastatic patients: a phase 2 study. Int J Radiat Oncol Biol Phys. 2022;114(4):762-770. doi:10.1016/j.ijrobp.2022.08.028
Feng XY, Li J, Li AM, Jing SH, Zhu XX, Wang Z. Stereotactic body radiotherapy for recurrent and oligometastatic soft tissue sarcoma. World J Surg Oncol. 2022;20(1):322. doi:10.1186/s12957-022-02781-1
Baumann BC, Bernstein KA, DeLaney TF, et al. Multi-institutional analysis of stereotactic body radiotherapy for sarcoma pulmonary metastases: high rates of local control with favorable toxicity. J Surg Oncol. 2020;122(5):877-883. doi:10.1002/jso.26078
Gutkin PM, von Eyben R, Chin A, et al. Local control outcomes using stereotactic body radiation therapy or surgical resection for metastatic sarcoma. Int J Radiat Oncol Biol Phys. 2022;114(4):771-779, doi:10.1016/j.ijrobp.2022.05.017
Tinkle CL, Singh C, Lloyd S, et al. Stereotactic body radiotherapy for metastatic and recurrent solid tumors in children and young adults. Int J Radiat Oncol Biol Phys. 2021;109(5):1396-1405, doi:10.1016/j.ijrobp.2020.11.054
van der Graaf WTA, Blay JY, Chawla SP, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo controlled phase 3 trial. Lancet. 2012;379(9829):1879-1886. doi:10.1016/s0140-6736(12)60651-5
Mir O, Brodowicz T, Italiano A, et al. Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, Phase 2 trial. Lancet Oncol. 2016;17(12):1732-1742. doi:10.1016/s1470-2045(16)30507-1
Gaspar N, Marshall LV, Binner D, et al. Joint adolescent-adult early phase clinical trials to improve access to new drugs for adolescents with cancer: proposals from the multi-stakeholder platform-ACCELERATE. Ann Oncol. 2018;29(3):766-771, doi:10.1093/annonc/mdy002
Weiss AR, Chen YL, Scharschmidt TJ, et al. Outcomes following preoperative chemoradiation +/- pazopanib in non-rhabdomyosarcoma soft tissue sarcoma (NRSTS): a report from Children's Oncology Group (COG) and NRG Oncology. J Clin Oncol. 2022;40(suppl 16):11504. doi:10.1200/JCO.2022.40.16